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Abstract
Refolding of viral class-1 membrane fusion proteins from a native state to a trimer-of-hairpins structure promotes entry of
viruses into cells. Here we present the structure of the bovine leukaemia virus transmembrane glycoprotein (TM) and
identify a group of asparagine residues at the membrane-distal end of the trimer-of-hairpins that is strikingly conserved
among divergent viruses. These asparagines are not essential for surface display of pre-fusogenic envelope. Instead,
substitution of these residues dramatically disrupts membrane fusion. Our data indicate that, through electrostatic
interactions with a chloride ion, the asparagine residues promote assembly and profoundly stabilize the fusion-active
structures that are required for viral envelope-mediated membrane fusion. Moreover, the BLV TM structure also reveals a
charge-surrounded hydrophobic pocket on the central coiled coil and interactions with basic residues that cluster around
this pocket are critical to membrane fusion and form a target for peptide inhibitors of envelope function. Charge-
surrounded pockets and electrostatic interactions with small ions are common among class-1 fusion proteins, suggesting
that small molecules that specifically target such motifs should prevent assembly of the trimer-of-hairpins and be of value as
therapeutic inhibitors of viral entry.
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Introduction
Bovine Leukemia Virus (BLV) and Human T-Cell Leukemia
Virus Type-1 (HTLV-1) are related deltaretroviruses that cause
aggressive lymphoproliferative disorders in a small percentage of
infected hosts [1,2,3,4,5,6]. Like other enveloped viruses, retrovi-
ruses must catalyse fusion of the viral and target cell membranes to
promote entry of the viral capsid into the target cell. The retroviral
class I fusion protein consists of the transmembrane glycoprotein
(TM) component of the envelope glycoprotein complex [7].
Envelope is displayed on the surface of the virus or infected cell as
a trimer, with three surface glycoprotein (SU) subunits linked by
disulphide bonds to a spike of three TM subunits [8].
Experimentally validated models suggest that SU-mediated
receptor engagement induces isomerisation of the inter-subunit
disulphide bonds and initiates a cascade of conformational
changes that activate the fusogenic properties of TM [9,10].
Membrane fusion is achieved by re-folding of the TM from a
native non-fusogenic structure through a rod-like pre-hairpin
intermediate, in which the C- and N-terminal segments are
embedded in the viral and target cell membranes respectively
[7,8]. The pre-hairpin intermediate then resolves to a trimer-of-
hairpins structure, which pulls the membranes together and
facilitates lipid mixing and membrane fusion [7,8,11,12]. For
several viruses membrane fusion is sensitive to inhibition by
peptides that mimic a C-terminal region of the trimer-of-hairpins
[13,14,15,16,17,18,19]. The C-terminal fragment of the HTLV-1
trimer-of-hairpins exhibits a short a-helical motif embedded in an
extended non-helical peptide structure referred to as the leash and
a-helical region (LHR) [20,21]. The LHR-based mimetics are
structurally distinct from the prototypic extensively a-helical
peptide inhibitors of human immunodeficiency virus but are
reminiscent of the leash regions observed in influenza haemag-
glutinin [20,21,22,23].
Importantly, amino acid residues that are required for potent
inhibitory activity of the HTLV-1 and BLV peptides are not fully
resolved in the available HTLV-1 TM structure, yet this
information is critical to the development of therapeutically
relevant peptide or low-molecular-weight inhibitors of HTLV-1
entry [17,22]. Moreover, other class I fusion proteins have
extended non-helical elements in the C-terminal region of the
trimer-of-hairpins and understanding how these elements contrib-
ute to the leash in a groove mechanism of fusion protein function
will have broad relevance to anti-viral therapies [23,24]. We
PLoS Pathogens | www.plospathogens.org 1 February 2011 | Volume 7 | Issue 2 | e1001268therefore sought to examine the structure and function of the BLV
TM and to compare this information with data derived from
diverse class I fusion proteins and the related HTLV-1 TM
structure.
Here we show the structure of the post-fusion conformation of
the BLV TM ectodomain and demonstrate that coordinated ions
and a network of hydrogen-bonded water molecules make critical
contributions to the assembly and stability of the trimer-of-hairpins
form of the BLV TM and are essential for TM-mediated fusion.
Additionally, we resolve a region of the LHR that is critical to the
activity of peptide inhibitors of HTLV-1 and BLV entry. We
provide evidence that basic residues in a membrane proximal
helical element of the LHR interact with charged residues that
surround an extended hydrophobic pocket on the coiled coil. This
charge-surrounded pocket represents an attractive target for
antiviral drugs. Our data indicate that coordinated ions and
charge-surrounded hydrophobic pockets are functionally signifi-
cant leitmotifs of class I fusion proteins.
Results
The structure of the BLV TM ectodomain
To obtain crystals for structural studies, the N- and C-terminal
limits of the coiled coil region of BLV TM were identified using
LearnCoil VMF [25]. The TM ectodomain, including the
predicted coiled coil and LHR from Ala326 to Trp418, were
fused to the C-terminal end of maltose binding protein via a three-
alanine spacer following the methodology of Center et al [26]. The
soluble purified protein was crystallised and the structure solved to
a resolution of 2.0 A ˚ (Fig. 1). As anticipated, the overall fold of the
BLV TM ectodomain is that of a trimer-of-hairpins, with the N-
terminal a-helices twisting around each other to produce the
central triple-stranded coiled coil that is characteristic of class I
fusion proteins. Buried leucine and isoleucine residues within the
coiled coil predominantly mediate the interactions between
monomers, but strikingly there are two polar layers within the
coiled coil that establish interactions with ordered water molecules
and a chloride ion respectively (see below). At the base of the
coiled coil the peptide backbone undergoes a 180u loop forming
the chain reversal region (Fig. 1A, B), within which is a short
helical segment containing the first cysteine of the conserved
CX6CC motif [9,10]. The predicted disulphide between Cys384
and Cys391 is reduced in the resolved structure but this does not
appear to affect the overall protein fold. In support of this view,
preliminary lower resolution structures obtained for crystals
formed in the absence of TCEP-HCL reveal an intact disulphide
(data not shown). These data indicate that the disulphide is not
essential for constraining the chain reversal region in the folded
protein, even though it might play a role in the folding process.
Therefore, the known defects in membrane fusion associated with
substitution of these cysteines are likely due to direct perturbation
of the inter-subunit disulphide isomerisation step of the envelope-
mediated membrane fusion process [9,10]. After Cys391, the LHR
begins with an extended non-helical leash followed by an eight-
residue a-helix. This helix is followed by a three-residue linker
incorporating a single proline, allowing a sharp kink in the LHR
prior to the start of a second a-helix that adopts an orientation
almost 90u to the first helical segment of the LHR (Fig. 1A, B, C).
A panel of mutants in BLV envelope are processed and
expressed identically in vivo
Guided by the crystal structure, a panel of mutants in BLV
envelope were designed to perturb key features of the trimer-of-
hairpins structure. A common difficulty with mutagenesis of viral
envelopes, particularly the TM, is that at particular positions even
conservative substitutions can dramatically impair the proteolytic
processing and cell surface expression of envelope [27,28].
Therefore, we compared each of the mutants with the parental
‘‘wild-type’’ envelope and confirmed appropriate expression,
processing and cell surface presentation of the TM mutants. No
significant differences in either the expression level of gp51 or the
cleavage of the precursor protein, gp72, were observed (Fig. 2A).
Moreover, flow cytometry analysis confirmed that in each case the
mutant envelope was displayed on the cell surface at levels
equivalent to wild type (Fig. 2B). Subsequently, the envelope-
expressing cells were used as effector cells in syncytium formation
assays, and the efficiency of each mutant envelope relative to wild-
type in catalysing membrane fusion was calculated as the relative
fusogenic index. The effect of each mutation on fusogenicity
(Fig. 2C), and the mutant phenotypes are interpreted with
reference to the crystal structure below.
Solvent molecules are critical for stable assembly of the
core coiled-coil
The trimerisation of the N-helices appears to be facilitated by
presentation of aliphatic residues to the interacting faces of the TM
monomers, thereby forming a hydrophobic core down the axis of
the central coiled coil. Notably, in the BLV trimer-of-hairpins
there are two positions along this interface that harbour polar
residues, Thr353 and Asn367 (Fig. 3A, B). Thr353 is located
approximately half way up the N-helix, and it is oriented such that
the methyl group of the side chain points toward the centre of the
coiled coil and the hydroxyl group faces toward the neighbouring
N-helix. In this position, Thr353 participates in a complex
network of hydrogen bonding via several buried ordered water
molecules. In particular, Thr353 makes a contact through one
water molecule with the main-chain of Glu397 and through a
separate water molecule to the side-chain of His354, one of the
residues which forms the wall of the groove into which the LHR
Author Summary
Human T-cell leukaemia virus types-1 (HTLV-1) and bovine
leukaemia virus (BLV) are divergent blood borne viruses
that cause hematological malignancies in humans and
cattle respectively. In common with other enveloped
viruses, infection of cells by HTLV-1 and BLV is dependent
on the membrane fusion properties of the viral envelope
glycoproteins. Here we have solved the crystal structure of
the BLV transmembrane glycoprotein, and, through a
functional and comparative analysis with HTLV-1, we have
identified features that are critical to fusion protein
function. In particular, we demonstrate that electrostatic
interactions with small ions dramatically stabilize the
assembly and fusion-associated forms of the BLV TM, but
are not required for the cell surface display of native pre-
fusogenic envelope. Moreover, we show that charged
residues that border a deep hydrophobic pocket contrib-
ute directly to appropriate folding of fusion-active
envelope and are critical to membrane fusion. Importantly,
the charged residues that border the pocket are key
features that determine the specificity and activity of
peptide inhibitors of envelope function. Our study
demonstrates that charge-surrounded pockets and elec-
trostatic interactions with small ions are significant
leitmotifs of diverse class-1 fusion proteins and that these
elements represent ideal targets for novel small-molecule
inhibitors of viral entry.
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which replaces threonine with a non-polar residue of equivalent
size, completely abrogates envelope-mediated membrane fusion
(Fig. 2C). Moreover, the introduction of the T353V substitution
into the pMBP-BLVhairpin vector yields a recombinant protein
that completely fails to trimerise (Fig. 3E). Interestingly, the data
demonstrate that substitutions at Thr353 do not affect expression,
processing, or surface expression of native envelope but severely
impair the fusogenic activity of envelope by preventing assembly of
the trimer-of-hairpins. Our data therefore provides further
evidence that the trimeric coiled coil likely forms during the
fusion process.
Interaction with chloride ions
A spherical density feature was observed on the central axis of
the molecule; comparison of refined temperature factors with
those of the surrounding protein atoms suggests an entity more
electron-dense than water. Based on the chemical environment,
the shape of the density and B factor comparisons we have
modeled this feature as a chloride ion. This chloride ion is situated
towards the chain reversal end of the coiled coil between a group
of three asparagines, one from each monomer of TM (Asn367).
These asparagine residues establish electrostatic interactions with
the chloride ion by creating a slightly positively charged
microenvironment between the N-helices. An alignment of
envelope sequences from diverse viral groups (Fig. 3C) reveals
that this asparagine is conserved. Moreover, comparison of the
crystal structures for the fusion protein ectodomains of HTLV-1
[20], MoMLV [29], Ebola [24,30], and Syncytin-1 [31], a protein
derived from a human endogenous retrovirus that plays a critical
role in the implantation of the trophoblast into the wall of the
uterus [32], show that the ability to coordinate chloride is retained
(Fig. 3D). To test the importance of the chloride interacting
asparagines, we introduced amino acid substitutions of similar size
and geometry. Introducing a leucine residue at position 367 of
BLV TM renders envelope entirely non-fusogenic. The N367L
substitution does not completely prevent trimerisation of the BLV
coiled coil in vitro but it significantly destabilises the trimer and a
large broad peak corresponding to higher order oligomers and
aggregated material is observed by gel filtration chromatography
(Fig. 3E). Interestingly, a substitution whereby Asn367 is replaced
by an aspartic acid residue produces a decrease in fusogenicity of
Figure 1. The BLV trimer-of-hairpins. (A) Crystal structure of the BLV trimer-of-hairpins shown as a cartoon, each monomer is differently
coloured. (B) Cartoon representation of the BLV hairpin monomer displaying the N-terminal helical region and chain reversal regions (red) and the
leash and helical regions (LHR, yellow). The membrane proximal end is at the top. (C) Detail of the interaction of the BLV LHR (yellow cartoon and
sticks), with the coiled coil shown in blue and red. Dashed lines represent potential hydrogen bonds. Important residues in the BLV coiled coil are
shown as sticks, key LHR residues are annotated. (D) Alignment of the BLV and HTLV-1 LHRs. Conserved residues are shown in red, semi-conserved in
blue and non-conserved in black. Structural diagrams were produced using PyMol (Amino acid coordinates are BLV Cys391-Gln419; and HTLV-1
Cys400-Leu429).
doi:10.1371/journal.ppat.1001268.g001
BLV TM Structure
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with a carboxylate group in the centre of the coiled coil, which
inverts the surface charge of the binding pocket, and therefore
would not support interaction with a chloride. In contrast to
N367L, the N367D mutation should maintain the hydrogen
bonding in and around the chain-reversal region mediated by the
carbonyl group that is common to both asparagine and aspartic
acid, and therefore the disruption of fusion should be due
primarily to the absence of the chloride ion, albeit we cannot
exclude the possibility that the close proximity of negatively
charged aspartate side chains impairs trimerisation. However, our
biological assays demonstrate that the N367D substitution, unlike
N367L, retains some membrane fusion activity. In vitro, rather than
producing a range of higher order species, the introduction of the
N367D mutation into pMBP-BLVhairpin produces a recombinant
protein with a major peak at an elution volume consistent with the
molecular weight of a tetramer rather than a trimer (Fig. 3E).
Tetramerisation is unlikely to be the reason for the compromised
fusogenic activity of the N367D-envelope; nonetheless, the results
demonstrate the importance of the chloride-interacting aspara-
gines to the stability of the trimeric coiled coil.
The interaction of the LHR with the coiled coil
Along the length of the LHR multiple contacts are made with
the coiled coil and such interactions are required for the activity of
inhibitory LHR-mimetic peptides [14,17,21,22]. Amino acid
residues that are critical determinants of peptide potency map to
the C-terminal region of the LHR [21,22], but key residues and
the manner in which they interact with the coiled coil are not
resolved in the published HTLV-1 TM structure [20]. A detailed
view of the BLV LHR bound to the coiled coil and a sequence
comparison of the HTLV-1 and BLV LHRs are shown in Fig. 1C
and D. Towards the N-terminus of the BLV LHR, conserved
residues Leu394 and Ile396 dock into a hydrophobic pocket on the
coiled coil, and an array of polar side chains at one side of the
pocket interact with the LHR peptide backbone (Fig. 1C). We
have previously demonstrated that interactions with the peptide
backbone contribute to the activity of the BLV and HTLV-1
peptide inhibitors [17,22]. By contrast, the side chain of Arg395
projects out into solvent suggesting that this residue is not essential
for interaction of the LHR with the coiled coil or for trimer-of-
hairpins formation (Fig. 1C). In keeping with this view, the R395A
substitution has no significant effect on envelope fusogenicity
(Fig. 2C) and therefore serves as a useful control for our analysis of
envelope structure and function. As the N-helices twist around one
another the groove between them accommodates the first
conserved a-helical segment of the LHR. Within this a-helix,
BLV residues Ile401 and Leu404 extend down and pack into the
groove (Fig. 1C). Significantly, substitution of Leu404 with alanine
results in an 80% loss of fusogenic activity relative to wild type
(Fig. 2C), indicating that this interaction contributes substantially
to the stability of the LHR/coiled coil interaction.
The first a-helix of the BLV LHR ends at Asp406, and between
the end of this helix and the beginning of the next is a three-
residue linker, comprised of Leu407, Gln408 and Pro409.
Figure 2. Expression and fusogenicity of mutant BLV enve-
lopes. A panel of 10 mutants in BLV envelope was generated using
site-directed mutagenesis of the pCMV-BLVenv-RRE vector. The
envelopes (or empty pCDNA3.1 for the mock sample) were transfected
with pRSV-Rev into HeLa cells, and the cells were split into three
aliquots, one sample was lysed for Western analysis, another stained
and examined by flow cytometry, and the third used as effector cells in
syncytium formation assays with non-transfected HeLa cells as target
cells. (A) Western blot probed for SU (upper panel) and actin (lower
panel). Upper band is the Env precursor, gp72, lower bands gp51. (B)
Flow cytometry analysis using the same primary antibody as in (A),
detected with FITC-labelled anti-mouse IgG. Solid histograms represent
mock transfected cells, shown alone in the first panel, and open
histograms represent the envelope transfected cells. (C) Fusogenicity of
the mutant envelopes. Fusogenic index represents the number of
nuclei in a low-power light microscope field present in syncytia as a
percentage of the total nuclei in the field (Data represent the means
from triplicate assays 6SD).
doi:10.1371/journal.ppat.1001268.g002
BLV TM Structure
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between N-helices, a ridge across this groove prevents Leu407
from docking particularly deeply (Fig. 1C). This Leucine is not
conserved among leukaemia viruses. Instead, there is an Arginine
residue at this position of the HTLV-1 LHR that makes contact
with the coiled coil. Such differences may account, in part, for the
specificity and significant differences in potency that are observed
for the BLV and HTLV-1 peptide inhibitors [17]. The conserved
proline (BLV Pro409) of the extended non-helical linker induces a
sharp kink in the LHR thereby allowing a second a-helix to bind
almost directly across the groove, at right angles to the rest of the
LHR. Crucially, this second helix is not resolved in the published
HTLV-1 TM structure [20]. At the point at which this change of
direction occurs, a conserved leucine, Leu410, docks into the start
of a deep hydrophobic pocket. Adjacent to Leu410 in this pocket
and within the second LHR helix is Val414, which is also
conserved in HTLV-1 (Fig. 1C, D). Substitution of either Leu410
or Val414 with alanine markedly impairs the fusogenic function of
envelope (Fig. 2C). The substitution of L410A is somewhat more
detrimental than substitution of Val414, with an activity loss of
75% and 65% respectively.
Embedded within the second helical element of the LHR is an
arginine (Arg413) that participates in electrostatic interactions with
the coiled coil (Fig. 1C). This residue is conserved in HTLV-1 and
is critical to the inhibitory activity of the HTLV-1 LHR mimetic
peptide P
cr-400 [22]. Intriguingly, Arg413 projects back along the
axis of the coiled coil and binds between Leu407 and Leu410,
where it forms hydrogen bonds with Gln343 from the same N-
helix and Asp342 from an adjacent N-helix and also donates a
hydrogen bond, through the e-nitrogen, to the main chain
carbonyl of Glu408 of the LHR (Fig. 1C). The substitution of
Arg413 with alanine dramatically disrupts the fusogenic activity of
envelope and reduces envelope function by more than 90%
relative to wild type (Fig. 2C). Moreover, Arg413 cannot be
functionally replaced by lysine. The R413K mutant, while more
fusogenic than the alanine substituted derivative, is still 85% less
effective at catalysing membrane fusion than wild-type envelope
(Fig. 2C). These data indicate that the electrostatic and hydrogen
bonding interactions made by Arg413 are essential to the
envelope-mediated membrane fusion process.
Contrasting effects of two arginine residues on the
stability of the trimer-of-hairpins
Based on homology modelling, we previously suggested that
Arg403 of the LHR projects out from one side of the a-helix and is
repelled electrostatically by N-helix residue Arg345 [17]. This
prediction is substantiated by the crystal structure presented here
(Fig. 1C). Moreover, the R403A substitution yields an envelope
that produces extensive syncytia and is significantly more fusogenic
than wild-type envelope (Fig. 2C and Fig. 4C). Thus, the
substitutions R403A and R413A have very different effects on
the fusogenicity of BLV envelope, increasing activity by over two-
fold and almost completely abolishing activity respectively (Fig. 2C
and 4C). Using a modified thermal aggregation assay [33], we
assessed the relative effects of these two substitutions on the
thermostability of the BLV trimer-of-hairpins. Control experi-
ments revealed that after a five minute incubation at 40uC, on
average 53% of the wild-type MBP-BLV-hairpin protein was
present in high-order aggregates (Fig. 4A, B). However, when the
same heat treatment was applied to the protein bearing the R403A
mutation, we found that only 37% of protein aggregated. The
difference to wild-type hairpin was significant (P#0.005, t-test)
(Fig. 4A, B). By contrast, the R413A substitution resulted in
aggregation of over 70% of total protein, again a significant
difference to wild type (P#0.005, t-test) (Fig. 4A and B). Notably,
even without heat treatment over 50% of the R413A protein was
aggregated (Fig. 4A). Furthermore, these relative differences in the
propensity of the recombinant proteins to aggregate were
maintained following heat treatment at 50 and 60uC (Fig. 4B).
Hence, the contrasting effects of the arginine substitutions on
envelope fusogenicity are directly due to changes in stability of the
post-fusion trimer-of-hairpins structure.
Reduced sensitivity to peptide inhibitors
A prediction based on the increase in thermal stability of the
R403A substituted trimer-of-hairpins is that such substitutions
should confer reduced sensitivity to LHR-mimetic peptide inhib-
itors. To test this view we compared the activity of the P
BLV-391
antagonist of envelope fusion [17] against wild type or R403A-
substituted envelope. This peptide mimics residues Cys391 to
Gln419 of BLV Env. In syncytium interference assays, P
BLV-391
inhibited fusion catalysed by wild-type envelope with an IC50 of
3.1760.09 mM (Fig. 4D). However, P
BLV-391 only inhibited fusion
catalysed by R403A envelope with an IC50 estimated to be .9 mM,
and even at peptide concentrations up to 15 mM inhibition of
syncytium formationwas markedly damped indicating that both the
potency and efficacy of the peptide was reduced against R403A
substituted envelope (Fig. 4D). Moreover, though more active
against native envelope, a reciprocally substituted peptide antago-
nist, P
BLV-R403A, failed to exhibit full potency against the R403
envelope derivative; P
BLV-R403A inhibited wild-type envelope
catalysed membrane fusion with an IC50 of 1.360.1 mM, but
inhibited the R403A envelope with an IC50 of .6 mM (Fig. 4E). In
both experiments, C34 (a peptide mimetic of HIV-1 gp41 residues
Gly627 to Leu661) was used as a negative control. Thus, improving
thethermal stabilityof the trimer-of-hairpins form of a class-1fusion
protein significantly reduces the sensitivity of envelope to peptide
inhibitors targeted to the coiled coil.
A critical site for the binding of HTLV-1 small molecule
fusion inhibitors
The structure of the C-terminal segment of the BLV LHR and
the accumulated data suggest a key role for the conserved arginine
Figure 3. Role of solvent molecules in the trimerisation of the coiled coil. (A) and (B) Slice through the BLV trimer-of-hairpins showing the
network of ordered small molecules in the coiled coil co-ordinated by Thr353 (A) and Asn367 (B). N-helices are shown as green ribbons with
important residues shown as sticks and coloured according to atom type (green is carbon, red is oxygen and blue is nitrogen). LHRS are shown in
turquoise. Red spheres represent ordered water molecules, the green sphere central in (B) represents a chloride ion. (C) Clustal W alignment of a
small region of the N-helices from several viruses. Completely conserved residues are coloured yellow, semi-conserved in green. Note conservation of
Asn367 (BLV co-ordinates), Arg368 and Asp372. (D) Structural superimposition of a slice through the coiled coils of BLV (green), HTLV-1 (yellow, PDB
ID 1MG1), Syncytin (white, PDB ID 1Y4M), MoMLV (turquoise, PDB ID 1MOF) and Ebola (purple, PDB ID 2EBO). Alpha helices are shown as cartoons,
conserved Asn367 (BLV co-ordinates), Arg368 and Asp372 are shown as sticks. The green sphere represents the chloride ion. (E) Gel filtration
chromatography elution profiles of bacterially expressed MBP-hairpin constructs, with MBP fused to the wild type or mutant BLV TM ectodomain as
indicated. Molecular weights indicated were determined using protein standards. ‘‘A’’ denotes aggregated material, ‘‘T
H’’ denotes trimer-of-hairpins,
‘‘M’’ denotes monomeric protein.
doi:10.1371/journal.ppat.1001268.g003
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fusion. Moreover, our recent data indicate that the equivalent
arginine residue, Arg422, of the HTLV-1 LHR-mimetic peptide is
critical to inhibitory activity [22]. Notably, for the HTLV-1 LHR-
based inhibitor residues equivalent to Leu413, Arg416 and
Leu419 are also of importance to the biological activity of the
peptide [21,22]. We therefore sought to establish whether or not
the conserved arginine in the HTLV-1 LHR docks with the coiled
coil in a similar manner to that of BLV and if this residue is
important to membrane fusion mediated by the HTLV-1 TM. We
generated a small panel of mutants in HTLV-1 envelope,
substituting Arg416 of the LHR with alanine and lysine (R416A
and R416K), and making similar substitutions for Arg422 (R422A
and R422K). Using a monoclonal antibody recognising HTLV-1
SU, we confirmed by Western blotting and flow cytometry that all
four mutant envelopes were expressed and post-translationally
processed in a manner identical to wild type (Fig. 5A, B). In
syncytium formation assays, the individual alanine substitutions of
Arg416 and Arg422 resulted in envelopes that are 91% and 97%
less fusogenic than wild-type envelope respectively (Fig. 5C).
Figure 4. Contrasting effects of alanine substitutions at key arginine residues in the BLV coiled coil. R403A and R413A mutations were
introduced into the MBP-BLV Hairpin vector, expressed and purified in bacteria and run over a size exclusion column to purify the trimeric species.
The trimer-of-hairpins was then re-run over the column with or without heat treatment for 5 mins at 50uC. (A) Gel filtration elution profiles of non-
heat treated (solid lines) or heat treated (dashed lines) mutant BLV MBP-hairpin proteins. Molecular weights indicated were determined using protein
standards. (B) The area under the peaks corresponding to aggregated material from gel filtration experiments (example traces in (A)) was calculated
as a percentage of the sum of the areas under both the aggregate peaks and the peaks corresponding to the trimeric species. Columns show the
means from two experiments following heat treatment at each of the three temperatures shown. (C) Images of typical Giemsa-stained syncytia
formed when cells transfected with wild-type, R403A or R413A BLV envelope expression constructs were used as effector cells in syncytium formation
assays. (D) and (E) Membrane fusion induced by the R403A mutant envelope is less sensitive to inhibition by LHR-mimetic peptides. HeLa cells
transfected with either wild-type or R403A mutant were used as effector cells in syncytium formation assays, in the presence of increasing amounts of
BLV LHR mimetic peptide based on wild type LHR (P
BLV-391, (D)), or, alternatively, incorporating the R403A substitution (P
BLV-R403A, (E)) or control
peptide (C34, HIV inhibitor). Data represent the mean 6SD from triplicate assays (syncytia from 5 low power light microscope fields were scored).
doi:10.1371/journal.ppat.1001268.g004
BLV TM Structure
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envelope that was not significantly less fusogenic than wild type
(P.0.05, t-test) (Fig. 5C). However, Arg422 could not be
functionally replaced with lysine, the R422K mutation resulted
in an 88% reduction in fusogenic activity. Taken together with the
data from the BLV R413K mutant, this suggests that HTLV-1
R422 adopts a near-identical conformation to BLV R413 at the C-
terminal segment of the LHR.
The likely conservation of position and orientation of HTLV-1
R422 in the trimer-of-hairpins allowed us to construct a model for
the binding of the C-terminal segment of the HTLV-1 LHR to the
coiled coil (Fig. 5D). The model suggests that R422 could bind to a
negatively charged ridge that is orientated across the groove
between N-helices and that lies between the binding pockets for
Leu413 and Leu419 and that R422 docks adjacent to R416. As
such, four critical interactions between LHR side chains and the
coiled coil are contained within a binding hotspot of ,16 A ˚ x
,8A ˚ and disruption of these interactions profoundly impairs
envelope-mediated membrane fusion.
Discussion
There is greater sequence divergence between BLV and
HTLV-1 than, for example, between SIV and HIV-1 [34,35],
nonetheless the crystal structures of the BLV and HTLV-1 trimer-
of-hairpins are similar. The incorporation of ordered water
molecules and ions to facilitate trimerisation of the coiled coil
and assembly of the trimer-of-hairpins is seen in several viral fusion
proteins [20,29,30,36]. The crystal structure of SIV gp41
implicates multiple water molecules in the folding of the trimer-
of-hairpins [37]. However, the number of water molecules
concentrated in one region of the BLV coiled coil is unusual.
The interaction of Thr353 with an array of water molecules
appears to play a critical role in assembly of the coiled coil, as
substitution of T353 eliminates both in vitro trimerisation and in vivo
fusogenicity. Notably, for HTLV-1 the threonine residue is
replaced by an asparagine, which by virtue of its larger side chain
directly hydrogen bonds with the adjacent N-helix. By contrast,
Thr353 of BLV makes this contact through water-mediated
hydrogen bonds. However, the contribution of polar interactions
to coiled coil assembly is maintained at this location in HTLV-1 by
interaction of a chloride ion on the symmetry axis of the coiled
coil. Moreover, for both viruses three conserved asparagine
Figure 5. Basic residues in the C-terminal of the HTLV-1 LHR
contact the coiled coil. The pCMV-HTLVenv-RRE construct and
derivatives encoding substitutions of Arg416 or Arg422 of HTLV-1
envelope were co-transfected with pRSV-Rev into HeLa cells, empty
pCDNA3.1 transfected with pRSV-Rev was used as a negative control.
Transfected cells were processed as in Fig. 3. (A) Western blot probed
for HTLV SU (upper panel) or actin (lower panel); b-mercaptoethanol
was used during sample preparation. (B) Flow cytometry of envelope
expressing HeLa cells. Solid purple histogram illustrates the fluores-
cence profile of control cells, open green histograms show the
fluorescence profile of cells transfected with the indicated envelope
construct, all cells were probed for surface displayed envelope. (C)
Fusogenicity of HTLV-1 C-terminal LHR arginine mutants. The fusogenic
index was calculated as described (mean 6SD from triplicate assays).
(D) A ‘‘hotspot’’ for binding of HTLV-1 fusion inhibitors based on the
previously published HTLV-1 structure and modelled incorporating the
data from this study. Four key residues (Leu413, Arg416, Leu419 and
Arg422, shown as yellow sticks) interact with the HTLV-1 coiled coil
(grey space-filling model, region interacting with LHR residues shown in
red) within a compact binding site. The contact made by Arg422 is
critical to the binding and functional activity of HTLV-1 peptide
inhibitors.
doi:10.1371/journal.ppat.1001268.g005
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interact with a chloride ion. The properties of the N367L
substitution and the failure of N367D to rescue envelope function
indicate that the observed chloride-mediated interactions are
essential for stable assembly of the coiled coil and for TM-
mediated membrane fusion. Significantly, the asparagine (Asn367)
and adjacent arginine (Arg368) residues of BLV are conserved
between BLV, HTLV-1 and a number of disparate viral fusion
proteins, and the ability of the asparagines to interact with a
chloride ion is maintained. Critically, the chloride ion is present
within the post-fusion conformation of Ebola GP2 (30), but is
conspicuously absent in a pre-fusion structure resolved by Lee et al
[38] wherein the conserved asparagines adopt a more open
arrangement and the coiled coil is only partially trimerised. We
suggest that Asn367, as a direct consequence of conformational
changes in SU resultant from receptor binding, and in concert
with the equivalent asparagines from neighbouring monomers,
mediates electrostatic interactions with a chloride ion, which
brings the N-helices together, thus driving the trimerisation of the
coiled coil to yield the pre-hairpin intermediate in an event pivotal
to successful fusion. In addition, our results indicate that
trimerisation of the N-terminus of TM is not a requirement for
Env maturation and surface display of trimeric pre-fusogenic
envelope, offering a novel insight into the conformation of
retroviral Env spikes prior to activation. Taken together, the data
suggest that while the ‘‘knobs-into-holes’’ interactions of aliphatic
residues at the centre of the coiled-coil regions of class 1 viral
fusion proteins are important for trimerisation of the fusion-active
coiled coil the polar layers among these hydrophobic interactions
are critical. This information should be considered when designing
trimeric immunogens based on the coiled coil of TM. Moreover,
the structure in and around the chloride-interacting region has
been conserved in diverse viral fusion proteins and may be
susceptible to coiled coil destabilising drugs.
It is interesting to note that removal of a steric clash between
R403 and the BLV coiled coil yields an envelope that is more
fusogenic than wild type. For HTLV-1 an isoleucine, at a position
equivalent to residue Arg403 in the BLV LHR, also appears to
make a steric clash with the coiled coil and an alanine substitution
of this residue in the context of an LHR-based peptide inhibitor
yields a peptide with improved coiled coil-binding properties and
increased inhibitory activity [21]. It is therefore clear that viral
envelope has not evolved to optimise LHR binding to the coiled
coil or to maximise fusogenicity. One plausible explanation is that
membrane fusion needs to be kept in check. An overly fusogenic
envelope may induce rampant membrane fusion and syncytium
formation leading to cell death by apoptosis and thereby provide
additional stimuli for a robust anti-viral immune response. Clearly,
sub-optimal LHR/coiled-coil interactions have been maintained
during viral evolution and suggest that the development of
compounds that bind to the coiled coil with higher affinity than
the LHR may be an achievable anti-viral strategy.
The most notable difference between the HTLV-1 and BLV
TM structures is the resolution of a second helical motif within the
LHR of the trimer-of-hairpins. Residues that form the start of the
second a-helix are conserved in HTLV-1 and are critical to
envelope-catalysed membrane fusion and to the inhibitory activity
of LHR-mimetic peptides [21,22]. Just three residues from the end
of our structure is the first tryptophan of a conserved tryptophan-
rich membrane-proximal region (MPR). The MPR is believed to
interact with the opposing membranes during the fusion process
and substitution of the aromatic residues severely compromises,
but does not abolish, membrane fusion [39]. The conformation of
the MPR has received considerable attention because broadly
neutralising anti-HIV-1 antibodies bind epitopes contained within
the MPR [40,41]. It is likely that the HIV MPR adopts a helical
structure when interacting with membranes and the coiled coil
during fusion [40,42]. Examination of the BLV envelope sequence
and TM structure suggests that the second helical segment of the
LHR is likely to continue and that in the fusion-activated state the
tryptophan-rich MPR is also helical and inserted into the
membrane at an oblique angle. For the leukaemia viruses, the
conserved arginine (Arg413 in BLV), assists in defining the
orientation of the MPR, as the interactions of Arg413 with the
coiled coil and the LHR backbone propagate a sharp kink in the
LHR towards the membrane-proximal end of the coiled coil. A
lysine substitution of Arg413 retains only ,10% of the fusogenic
activity of wild-type envelope lending further support to this view.
The BLV crystal structure and our analysis of HTLV-1 and
BLV envelope-mediated membrane fusion reveal an important
role for electrostatic interactions in binding of the LHR to the
grooves of the coiled coil. For both BLV and HTLV-1 a conserved
basic residue in the second helical segment of the LHR interacts
with the charged rim of a deep pocket lined by non-polar residues.
For HTLV-1 the contribution of charge is enhanced by the
interaction of an additional basic residue (Arg416) with the
opposite rim of the pocket. Thus, while the insertion of non-polar
residues into hydrophobic pockets likely drives the docking of the
LHR with the coiled coil, we suggest that it is the electrostatic
attraction and hydrogen bonding of charged side chains around
these hydrophobic interactions that serves to ‘‘cement’’ the LHR
in place and thereby establish the precise geometry and affinity of
this interaction. In keeping with this view, substitution of these
basic residues ablates envelope-mediated membrane fusion and
dramatically impairs the inhibitory and coiled-coil-binding
properties of LHR-based peptides [22]. Moreover, only one of
these important basic residues is conserved in BLV compared to
HTLV-1 and it is notable that the synthetic BLV LHR-mimetic is
approximately 10-fold less potent than the corresponding inhibitor
of HTLV-1 [17]. Examination of the electrostatic surfaces of BLV,
HTLV, HIV and MoMLV coiled coils reveals, in each case, the
presence of a pocket surrounded by charged residues, though the
polarity of the charge and positioning along the groove is variable
(Fig. 6). The importance of the pocket and surrounding charge to
the assembly of the trimer-of-hairpins and the potency of C-helix-
based mimetic peptides has been demonstrated for HIV [43,44],
and taken with our findings for BLV and HTLV-1 suggest that
such charged regions are critical to retroviral envelope-mediated
membrane fusion in general. We suggest that structure-assisted
design of small molecules to target these charge-surrounded
pockets is a viable objective for anti-retroviral therapy.
We expect that the data produced in this study will be pivotal to
the development of more drug-like inhibitors of HTLV-1 envelope
catalysed membrane fusion, and thereby provide therapeutic
antiviral agents for adult T-cell leukaemia and HTLV-associated
myelopathy/tropical spastic paraparesis, diseases for which there
are currently no effective treatments [45,46].
Methods
Plasmid
The plasmids pCMV-BLVenv-RRE and pRSV-Rev have been
described [17,47]. To construct pCMV-HTLVenv-RRE the BLV
env sequences in pCMV-BLVenv-RRE were replaced by a HTLV-
1 env coding region amplified by PCR from pHTE-1 [48]. To
construct the plasmid pMAL-gp30hairpin (MBP-BLV-hairpin), a
modified fragment of the MBP open reading frame from pMAL-
c2 (New England Biolabs) with a 59 BglII site and a 39 PvuII site
BLV TM Structure
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encoding amino acid residues 326 to 418 was PCR amplified with
a5 9 PvuII site and a 39 PstI site. The PCR fragments were ligated
into a pMAL-c2 backbone digested with BglII and PstI. The
Quikchange mutagenesis kit (Stratagene) was used to introduce
point mutations into pCMV-BLVenv-RRE and pMAL-gp30hair-
pin following the manufacturer’s instructions.
Expression and purification of the recombinant
trimer-of-hairpins
Expression of the MBP fusion protein was carried out as
previously described [14,49]. Briefly, Escherichia coli BL21(DE3)
cells transformed with the MBP-BLV-hairpin vector were grown
at 37uC with vigorous shaking in LB supplemented with 10 mM
glucose and 100 mgml
21 ampicillin until an optical density at
600 nm of ,0.6 was reached. Protein expression was induced with
Isopropylthio-b-D-galactoside (IPTG) at a final concentration of
0.5 mM for 4 h at 37uC. Cells were harvested by centrifugation
and the pellet was resuspended in column buffer (20 mM Tris-
HCl [pH 7.5], 200 mM NaCl, 1 mM EDTA) supplemented with
protease inhibitors (1 mM phenylmethylsulfonyl fluoride and
1 mgml
21 aprotinin) and frozen O/N at 220uC. The cell
suspension was thawed and the cells lysed by sonication. Cell
debris was pelleted by centrifugation at 9,0006g for 30 min. The
crude lysate was diluted 1:5 in column buffer and loaded onto an
amylose column pre-equilibrated with column buffer. The column
was then washed with 15 column volumes of column buffer, and
the bound protein was eluted with column buffer supplemented
with 10 mM maltose.
Protein crystallization and structure determination
The trimeric recombinant MBP-BLV-hairpin protein was
purified by Superdex 75 gel filtration, and the required fractions
pooled and concentrated to 12 mg ml
21. Tris [2-carboxyethyl]-
phosphine hydrochloride (TCEP-HCl) was then added to a final
concentration of 5 mM. Protein concentration was estimated by
absorbance measured at 280 nm. Crystallization conditions were
identified using the sitting drop vapour diffusion technique, with
crystal screens from Hampton Research and Emerald Biostruc-
tures. Optimal crystallization was achieved by streak seeding with
a reservoir solution composed of 24.5% (v/v) isopropanol, 13.5%
(v/v) PEG-4000 and 0.1 M sodium citrate pH 5.6, and optimal
diffraction was achieved using a cryoprotectant composed of
mother liquor supplemented with 20% (v/v) glycerol. Diffraction
data was collected at beamline BM14 at the European
Synchrotron Radiation Facility (ESRF) in Grenoble. The structure
was solved by molecular replacement using a truncated model of
MBP-HTLV Hairpin (PDB ID 1MG1). Refinement proceeded
through cycles of model building using Coot and O [50,51] and
refinement using REFMAC5 [52]. Data and refinement statistics
are given in Table 1. The atomic coordinates and structure factors
(code 2XZ3) have been deposited in the Protein Data Bank,
Research Collaboratory for Structural Bioinformatics, Rutgers
University, New Brunswick, NJ (http://www.rcsb.org/).
Figure 6. Electrostatic surface analysis of retroviral coiled-coils reveals the presence of key charged-surrounded pockets. The coiled
coil surface of BLV (A), HTLV-1 (B), HIV (C) and MoMLV (D) is coloured according to electrostatic local protein contact potential using AMBER99
charges and radii, where blue represents net positive charge and red indicates net negative charge (+84.019 to -84.019 (kT/e)). Insets show the whole
coiled coil surface, with the region magnified circled in yellow.
doi:10.1371/journal.ppat.1001268.g006
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Peptides were synthesised using standard solid-phase Fmoc
chemistry and unless stated otherwise have acetylated N-termini
and amidated C-termini. The peptides were purified by reverse-
phase high-pressure liquid chromatography and verified for purity
by MALDI-TOF mass spectrometry. All peptides were dissolved
in dimethyl sulfoxide (DMSO), the concentration of peptide stock
solutions was confirmed by absorbance at 280 nm in 6M
guanidine hydrochloride and peptides were used at the final
concentrations indicated.
Cells and syncytium formation assays
HeLa cells were maintained in Dulbecco’s modified Eagle
medium supplemented with 10% foetal bovine serum (FBS). For
syncytium formation assays, HeLa cells were transfected with
equal quantities of pCMV-BLVenv-RRE (or empty pcDNA 3.1 for
mock samples) and pRSV-Rev using the GeneJuice transfection
reagent (Novagen). After 24 h, 3610
5 transfected cells were added
to 7.0610
5 non-transfected HeLa target cells in 6-well dishes
(Nunc), and cocultured for 16 hrs, in the presence of peptides
where appropriate. The cells were washed with phosphate-
buffered saline pH 7.4 (PBS), fixed using 3% paraformaldehyde
in PBS, and stained with Giemsa. Assays were performed in
triplicate. To calculate fusogenic indices, the fraction of nuclei
contained within syncytia in a 20x light microscope field was
expressed as a percentage of the total number of nuclei within the
field.
Western blotting
Western blotting was carried out using standard methods; b-
mercaptoethanol was used in sample preparation. BLV and
HTLV-1 envelope was detected using supernatant from murine
hybridoma cell lines expressing monoclonal antibodies raised
against recombinant antigen derived from BLV or HTLV-1
envelope, and anti-mouse horseradish peroxidase conjugated
secondary antibody at a dilution of 1:10,000 in PBS containing
5% (w/v) marvel and 0.025% Triton X-100.
Flow cytometry
To detect surface-expressed protein, cells transfected with the
appropriate envelope expression vector were detached from
culture flasks using PBS +2 mM EDTA, and washed twice with
PBS. 5.0610
5 cells were incubated with agitation for 1 hr at room
temperature in 1 ml DMEM +10% FBS containing 15 mgml
21
immunoglobulin purified from the BLV anti-Env antibody-
expressing hybridoma supernatant, or 150 ml supernatant from
the HTLV anti-Env antibody expressing hybridoma. Cells were
washed twice with PBS and incubated in the dark at room
temperature for 45 mins in DMEM containing anti-mouse FITC
(Sigma) at 1/1,000 dilution. Cells were washed once with PBS and
once with PBS +0.1% sodium azide before fixing with PBS +0.5%
paraformaldehyde. Bound fluorescence was detected using a
FACScan flow cytometer (Becton Dickinson).
Gel filtration chromatography
The oligomerisation states of MBP-BLV-hairpin and mutant
derivatives were examined by gel filtration using a Superdex 200
column equilibrated with MBP elution buffer. Fractions contain-
ing the trimeric species were retained. To assess the thermosta-
bility of the trimers, samples from these fractions were re-run over
the column either without heat treatment or with heat treatment at
the temperature specified for 5 min, followed by cooling for 2 min
on ice. The areas under the peaks observed were calculated, and
the area of the peak corresponding to the aggregate was expressed
as a percentage of the total area under both this peak and the peak
corresponding to the trimer.
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Table 1. Data collection and refinement statistics for
MBP-BLV-Hairpin.
Crystallographic Statistics
Space group R3
Cell dimensions a=b=107.60 A ˚, c=119.17 A ˚,
a=b=90u; c=120u
Resolution range (A ˚) 27.00 - 1.95
Total measurements 131833
Unique reflections 37148
Completeness 0.990 (0.904)
Rmerge 0.045
Redundancy 3.5 (2.9)
I/s(I) 23.9 (2.1)
Wilson B (A ˚2) 34.3
Matthew’s coefficient (A ˚3) 2.63
Solvent content 0.53
Number of protein residues 459
Number of solvent molecules 285
Number of other residues 1
R_work; R_free 0.1890; 0.2368
Average B-factor (A ˚2)
Overall 36.4
Protein Backbone 34.9
Protein side chains 37.1
Solvent 42.5
Other 27.1
RMSD Bonds (A ˚) 0.016
RMSD Angles (u) 1.65
Ramachandran plot statistics
[2] 91.8%
Most favoured region 8.2%
Additional allowed region N/A
Values in parentheses pertain to the highest resolution shell of 0.05 A ˚.
[2] as determined by PROCHEK.
doi:10.1371/journal.ppat.1001268.t001
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